Strong Revenue Growth:
Reported year-over-year software growth in 2024, alongside multi-year increases and net new client additions, indicates sustained commercial momentum. Customer penetration among large pharma is described as expanding across 2024–2025.
Investor Backing & Capital Strength:
A majority investment by GI Partners, with Summit Partners remaining a minority investor, is described as supporting further scale, product investment, and global reach. This signals access to resources for continued expansion.
Strong Market Position & Advantage:
Independent recognition as the highest-designated Leader in 2024 for life sciences clinical data and analytics platforms, coupled with adoption by numerous top biopharma companies, signals competitive strength in its core segment. Named client expansions further reinforce visibility and impact.
